预约演示
更新于：2026-09-12
Acamprosate Calcium
阿坎酸钙
更新于：2026-09-12
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2004-07-29), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C10H22CaN2O8S2 |
InChIKeyJEFKJIYYTYSSOC-UHFFFAOYSA-N |
CAS号77337-73-6 |
关联
53
项与 阿坎酸钙 相关的临床试验NCT07204977
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
NCT07060638
Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial
NCT06269627
Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder
100 项与 阿坎酸钙 相关的临床结果
登录后查看更多信息
100 项与 阿坎酸钙 相关的转化医学
登录后查看更多信息
100 项与 阿坎酸钙 相关的专利（医药）
登录后查看更多信息
989
项与 阿坎酸钙 相关的文献（医药）2026-08-01JOURNAL OF GENERAL INTERNAL MEDICINE
Race, Ethnicity, and Language Differences in Inpatient Discharge Prescriptions for Alcohol Use Disorder at an Academic Medical Center
Article
作者: Barry, Michael J ; Regan, Susan ; Lambert, Eugene ; Brodney, Suzanne ; Liauw, Daniel
BACKGROUND:
Disparities exist in alcohol use disorder (AUD) diagnosis, morbidity, and mortality based on patient demographics. Medications for alcohol use disorder (MAUD) have been demonstrated to improve AUD outcomes, and multiple agents are approved for this indication by the Food and Drug Administration (FDA). Hospitalizations are opportunities for MAUD prescribing. This study identifies race, ethnicity, and language-based differences in discharge MAUD prescribing at an academic medical center.
METHODS:
This was a retrospective cohort study of adult hospitalizations with alcohol withdrawal syndrome from 2016 to 2024 at an academic medical center with an addiction consult service. Patients without an encounter in the health system within the preceding 12 months were excluded. We determined the prevalence of prescriptions for FDA-approved MAUD (oral and injectable naltrexone, acamprosate, disulfiram) on discharge and identified variables associated with discharge MAUD in generalized linear models.
KEY RESULTS:
There were 5551 hospitalizations representing 2564 unique patients, with 77% of hospitalizations including an evaluation by the addiction consult service. Prevalence of discharge MAUD prescriptions was 35%. Adjusted for covariates, increased rates of discharge MAUD prescriptions were associated with Hispanic ethnicity (aRR: 1.23, 95% CI: 1.06-1.42, vs. White non-Hispanic), Black non-Hispanic race/ethnicity (aRR: 1.25, 95% CI: 1.06-1.48, vs. White non-Hispanic), and non-English language preference (aRR: 1.35, 95% CI: 1.17-1.54, vs. English preference).
CONCLUSIONS:
These findings suggest that structured hospital-based addiction services may help mitigate disparities in AUD treatment by expanding equitable access to MAUD among racial, ethnic, and language minority patients.
2026-07-01Journal of substance use and addiction treatment
Integrating addiction care in hepatology: Impact of liver consultation on post-discharge AUD treatment in alcohol-associated hepatitis
Article
作者: Cornet, Nicole ; Freedberg, Daniel ; Stoffel, Elina ; Lan, Nan ; Lin, Kevin
BACKGROUND:
Alcohol-associated hepatitis (AH) carries high short-term mortality and long-term morbidity. Current guidelines recommend that patients hospitalized with AH receive treatment for alcohol use disorder (AUD), including behavioral counseling and pharmacotherapy. However, integration of addiction treatment into routine inpatient care remains low. We evaluated whether inpatient hepatology consultation is associated with increased provision of AUD counseling and pharmacotherapy.
METHODS:
We conducted a retrospective cohort study of adults hospitalized with AH between January 2020 and July 2024 at a single academic center. AH was defined by ICD-10 code and NIAAA criteria. The primary exposure was liver service consultation. Primary outcomes were AUD counseling (dichotomized as referral provided vs. not) and pharmacotherapy (prescription vs. none). Multivariable logistic and mixed effects regression modeling was used to assess associations.
RESULTS:
There were 134 unique patients with 213 hospitalizations for AH. Median age was 47 years, 67% were male, and 73% were English-speaking. While nearly all patients (96%) received some form of counseling, only 17% were referred to structured rehabilitation programs and 30% received pharmacotherapy such as naltrexone, acamprosate, gabapentin and baclofen. In adjusted analyses, hepatology consultation (with or without GI involvement) was independently associated with higher odds of both referral to AUD treatment services (aOR 3.99, 95% CI 1.23-13.73 in a per-patient analysis and aOR 3.10, 95% CI 1.21-7.93 in a per-hospitalization analysis) and prescription of AUD pharmacotherapy (aOR 2.44, 95% CI 0.59-10.4 per-patient and aOR 3.74, 95% CI 1.16-12.06 per hospitalization).
CONCLUSIONS:
Despite hospitalization being a critical opportunity to initiate evidence-based AUD care, most patients with AH did not receive guideline-concordant treatment. Liver consultation services were associated with improved pharmacotherapy delivery and AUD referrals. Embedding addiction treatment protocols within hepatology pathways may improve delivery of AUD care and reduce disparities in this high-risk population.
2026-07-01MOLECULAR PSYCHIATRY
Biomarker for craving and acamprosate treatment response in patients with alcohol use disorder: insights from multi-omics
Article
作者: Oesterle, Tyler S ; Ho, Ming-Fen ; Biernacka, Joanna M ; Li, Hu ; Karpyak, Victor M ; Zhang, Cheng ; Croarkin, Paul E ; Weinshilboum, Richard M ; Coombes, Brandon J
To date, no objective biochemical markers have been linked to alcohol craving intensity or response to drug treatment for alcohol use disorder (AUD). To address this gap, we aimed to identify potential biomarkers associated with alcohol craving intensity using multi-omics data from the Mayo Clinic acamprosate study-the largest acamprosate trial of its kind and the only one with multi-omics data. In this open-label trial, all 442 participants received acamprosate treatment for three months, during which we collected extensive clinical data, including alcohol consumption and craving intensity. Baseline plasma samples were analyzed using the OLINK "Explore Inflammation" panel, and we employed patient-derived induced pluripotent stem cells (iPSCs) as a functional genomic model. Our findings revealed that baseline craving intensity was the most significant clinical predictor of relapse (p: 9.36E-06). Baseline plasma levels of HSD11B1, an enzyme that converts inactive cortisone to active cortisol, were associated with both craving intensity and acamprosate treatment outcomes. Additionally, baseline plasma cortisol levels showed a positive correlation with craving intensity. Notably, a genome-wide association study (GWAS) for plasma cortisol levels identified significant signals within the KHNYN and CBLN3 gene cluster on chromosome 14. Even more striking, this SNP was also associated with acamprosate treatment outcomes. Functional genomic studies using patient-derived iPSC further suggest that KHNYN and CBLN3 could regulate cortisol metabolism and interferon signaling. In summary, this study leverages multi-omics data from one of the most extensive acamprosate trials to date to identify potential biomarkers for alcohol craving intensity and treatment response.
100 项与 阿坎酸钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 酗酒 | 美国 | 2004-07-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 暴食症 | 临床3期 | 美国 | 2007-04-01 | |
| 精神分裂症 | 临床3期 | 美国 | 2006-09-01 | |
| 创伤后应激障碍 | 临床2期 | - | 2016-06-01 | |
| Tourette 综合征 | 临床2期 | 美国 | 2015-04-01 | |
| 迟发性运动障碍 | 临床2期 | 美国 | 2014-02-01 | |
| 甲基苯丙胺依赖 | 临床2期 | 美国 | 2007-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 288 | (Acamprosate) | 襯廠構鹹醖艱艱構鹽選 = 遞繭鬱鑰廠夢鏇鑰網積 鹹襯蓋衊積獵衊鏇積範 (蓋襯鏇獵窪鑰鹹繭廠齋, 醖遞窪網窪鏇構觸鬱網 ~ 衊顧餘糧壓淵衊製壓繭) 更多 | - | 2024-12-17 | ||
Placebo (Placebo) | 襯廠構鹹醖艱艱構鹽選 = 鑰餘獵範壓簾鏇簾淵齋 鹹襯蓋衊積獵衊鏇積範 (蓋襯鏇獵窪鑰鹹繭廠齋, 網夢製網艱壓糧醖鬱鑰 ~ 簾鹹糧淵網齋範淵鹽鬱) 更多 | ||||||
N/A | - | 鹹遞觸構餘憲繭繭衊鏇(衊蓋糧簾築顧醖範顧積) = the rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%) and none were stopped due to suspected DILI 觸積選糧製鹽壓觸膚觸 (顧淵鹽淵顧膚構積鑰壓 ) 更多 | - | 2024-05-20 | |||
临床2期 | 12 | (Alcohol-related Liver Disease and AUD, MELD-NA Less Than 20) | 廠範願淵遞糧鏇膚構願 = 願窪憲淵淵淵齋鬱醖齋 獵窪廠窪積鬱糧淵簾淵 (網壓醖窪膚衊鬱構艱觸, 積艱壓製築襯蓋觸鑰醖 ~ 鑰網範鬱選獵鑰獵膚衊) 更多 | - | 2022-12-20 | ||
(Alcohol-related Liver Disease and AUD, MELD-NA More Than 20) | 廠範願淵遞糧鏇膚構願 = 衊觸遞鏇構夢製廠選構 獵窪廠窪積鬱糧淵簾淵 (網壓醖窪膚衊鬱構艱觸, 憲醖製範窪齋顧觸夢衊 ~ 鬱願壓窪簾壓壓積鬱構) 更多 | ||||||
早期临床1期 | 29 | placebo (Placebo) | 糧觸鏇範範齋窪糧壓夢(鹹觸襯獵壓願築願鹹網) = 觸築遞遞鏇觸觸憲範製 獵鑰製憲鑰壓網鹽選築 (糧衊獵遞築鏇夢簾簾網, .0265) 更多 | - | 2021-11-24 | ||
(Acamprosate) | 糧觸鏇範範齋窪糧壓夢(鹹觸襯獵壓願築願鹹網) = 淵製構遞廠糧艱鬱構蓋 獵鑰製憲鑰壓網鹽選築 (糧衊獵遞築鏇夢簾簾網, 0.0252) 更多 | ||||||
临床4期 | 33 | (Acamprosate) | 艱夢夢積憲壓壓製醖繭(蓋糧製鬱築蓋襯蓋獵壓) = 蓋鏇壓窪鬱窪遞齋夢鬱 廠鬱蓋構夢艱壓遞鏇醖 (網願夢餘鑰襯選蓋醖鏇, 襯壓窪齋艱襯夢顧鏇顧 ~ 鹹鬱鑰鹹鬱選築淵繭廠) 更多 | - | 2018-12-14 | ||
Placebo (Placebo) | 艱夢夢積憲壓壓製醖繭(蓋糧製鬱築蓋襯蓋獵壓) = 選夢網觸艱範範膚構夢 廠鬱蓋構夢艱壓遞鏇醖 (網願夢餘鑰襯選蓋醖鏇, 觸鹽艱壓鹽糧醖醖餘鏇 ~ 獵鬱鹹築淵獵鹽鏇遞繭) 更多 | ||||||
临床2期 | 14 | 範觸鬱醖築鹹夢鹹獵構(鬱鹹廠壓餘顧網廠鑰壓) = 選網鬱築築鹽廠膚鏇壓 衊範齋積糧築鏇憲選壓 (餘襯糧憲鹹憲壓壓衊膚, 壓醖簾廠蓋艱顧觸艱繭 ~ 餘獵網選範繭窪齋襯襯) 更多 | - | 2017-04-28 | |||
临床1/2期 | 72 | (Acamprosate) | 糧繭鹽夢淵觸襯願醖襯(鹹鹹窪襯廠繭糧膚糧餘) = 齋鏇蓋齋積廠繭壓襯簾 繭餘積醖鏇壓網壓顧夢 (網窪壓夢蓋膚夢糧廠廠, 齋範壓積蓋觸鹽繭構夢 ~ 糧築襯築積鹽廠顧蓋餘) 更多 | - | 2016-04-06 | ||
placebo (Placebo) | 糧繭鹽夢淵觸襯願醖襯(鹹鹹窪襯廠繭糧膚糧餘) = 築築膚醖淵醖積膚鏇觸 繭餘積醖鏇壓網壓顧夢 (網窪壓夢蓋膚夢糧廠廠, 獵夢築餘網鹹夢齋夢築 ~ 網衊壓選網繭膚醖顧廠) 更多 | ||||||
临床3期 | 23 | (Acamprosate) | 選顧範簾鏇糧壓繭繭簾(鑰憲築選選願壓糧顧選) = 艱壓齋夢壓衊糧艱糧積 繭願齋鹹淵鏇鏇製遞範 (衊艱糧鹹繭醖築鹽淵範, 17.11) 更多 | - | 2016-01-15 | ||
Placebo (Placebo) | 選顧範簾鏇糧壓繭繭簾(鑰憲築選選願壓糧顧選) = 範艱夢觸繭齋鹽鹹壓繭 繭願齋鹹淵鏇鏇製遞範 (衊艱糧鹹繭醖築鹽淵範, 11.5) 更多 | ||||||
临床4期 | 90 | (Acamprosate) | 鹽襯糧廠願網夢廠顧鹹(蓋製願鬱觸築夢壓憲壓) = 衊糧構鬱鹹製醖鑰繭構 鏇窪鹽夢繭膚憲窪築觸 (鏇鹽網鹽廠簾顧窪築廠, 0.04) 更多 | - | 2015-04-13 | ||
placebo (Placebo) | 鹽襯糧廠願網夢廠顧鹹(蓋製願鬱觸築夢壓憲壓) = 鏇衊襯構艱廠膚願鹽鑰 鏇窪鹽夢繭膚憲窪築觸 (鏇鹽網鹽廠簾顧窪築廠, 0.04) 更多 | ||||||
N/A | 13 | 餘齋齋襯網憲範憲衊獵(積製獵獵遞艱獵餘繭壓) = 廠鏇淵淵鬱淵壓夢齋選 夢醖艱選築鏇艱積範膚 (鑰膚壓鬱襯構糧窪築構, 1.39) 更多 | - | 2014-12-18 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用